Responses

Download PDFPDF
Thresholds for antibiotic resistance at which we change empirical treatment choices
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Response to 'Thresholds for antibiotic resistance at which we change empirical treatment choices' (Postscript ADC November 2010, Volume 95, Issue 6)
    • Berit Muller-Pebody, Epidemiologist
    • Other Contributors:
      • Alan P. Johnson, Paul T. Heath, Ruth E. Gilbert, Katherine L. Henderson, Mike Sharland

    Dr. Millar raises the point that an alternative broader-spectrum (and more expensive) antibiotic combination could be considered for empirical therapy of neonates with suspected early-onset sepsis in preference to penicillin and gentamicin which (based on our data) he estimated to be ineffective for 6% of cases.

    We support Dr Millar's view on the importance of appropriate empirical antibiotic treatment for septi...

    Show More
    Conflict of Interest:
    None declared.